Izotropic Corporation Launches BreastCT.com to Promote Breast CT Technology for Dense Tissue Screening

Izotropic Corporation has launched BreastCT.com, a new online platform designed to advance awareness of dedicated breast CT technology and its potential to improve breast cancer screening outcomes. The medical device company, which is commercializing imaging-based products for more accurate breast cancer detection, diagnosis, and treatment, created the site as a central educational resource focused on its IzoView Breast CT Imaging System.

The platform specifically addresses the critical challenge of detecting cancer in the approximately 50% of women who have dense breast tissue, a population that faces higher risks of missed diagnoses with conventional mammography. With IzoView's engineering phase now complete, BreastCT.com will serve as an evolving resource through clinical study preparation, regulatory phases in the U.S. and globally, and ongoing awareness programs leading to commercial launch.

The content positions Izotropic within the broader medical imaging industry context by highlighting other public companies that successfully created new imaging categories, providing audiences with perspective on where IzoView could fit within the market ahead of regulatory and commercial milestones. The company's broader information can be found on its website at https://izocorp.com and through its profile on SEDAR at https://sedarplus.ca.

This initiative represents a significant step in addressing a major gap in breast cancer screening technology. Women with dense breast tissue often receive false negatives from traditional mammograms, potentially delaying critical diagnoses and treatment. The dedicated breast CT technology promises higher accuracy through three-dimensional imaging capabilities that can better penetrate dense tissue and provide clearer visualization of potential abnormalities.

The launch of BreastCT.com comes at a crucial time when awareness about breast density and its impact on screening effectiveness is growing among both medical professionals and patients. Several states have implemented laws requiring healthcare providers to inform women about their breast density and the limitations of mammography for dense tissue, creating increased demand for alternative screening technologies.

As the platform evolves alongside Izotropic's regulatory progress, it will likely serve as an important resource for healthcare providers, patients, and investors seeking to understand the potential impact of dedicated breast CT technology on improving early cancer detection rates and ultimately saving lives through earlier intervention opportunities.